{"id":"https://openalex.org/W2336448784","doi":null,"title":"Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer","display_name":"Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer","publication_year":2017,"publication_date":"2017-01-01","ids":{"openalex":"https://openalex.org/W2336448784","mag":"2336448784"},"language":"en","primary_location":{"id":"mag:2336448784","doi":null,"is_oa":false,"landing_page_url":"https://works.bepress.com/joan-schiller/30/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039791495","display_name":"Mark G. Kris","orcid":"https://orcid.org/0000-0002-7317-5341","observed_orcids":["https://orcid.org/0000-0002-7317-5341"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark G. Kris","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7317-5341","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084295219","display_name":"Ronald B. Natale","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ronald B. Natale","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008593691","display_name":"Roy S. Herbst","orcid":"https://orcid.org/0000-0003-2535-5847","observed_orcids":["https://orcid.org/0000-0003-2535-5847"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roy S. Herbst","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2535-5847","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113698410","display_name":"Diane Prager","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Diane Prager","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015680000","display_name":"Chandra Prakash Belani","orcid":"https://orcid.org/0000-0001-5049-5329","observed_orcids":["https://orcid.org/0000-0001-5049-5329"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chandra P. Belani","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5049-5329","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050185260","display_name":"Joan H. Schiller","orcid":"https://orcid.org/0000-0003-0990-1211","observed_orcids":["https://orcid.org/0000-0003-0990-1211"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joan H. Schiller","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0990-1211","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077352149","display_name":"Karen L. Kelly","orcid":"https://orcid.org/0000-0002-2235-6636","observed_orcids":["https://orcid.org/0000-0002-2235-6636"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karen Kelly","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2235-6636","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084194376","display_name":"H. Spiridonidis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Spiridonidis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078389632","display_name":"Alan B. Sandler","orcid":"https://orcid.org/0009-0004-5397-5247","observed_orcids":["https://orcid.org/0009-0004-5397-5247"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alan Sandler","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-5397-5247","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059538753","display_name":"Kathy S. Albain","orcid":"https://orcid.org/0000-0002-2899-2473","observed_orcids":["https://orcid.org/0000-0002-2899-2473"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathy S. Albain","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2899-2473","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039180386","display_name":"David F Cella","orcid":"https://orcid.org/0000-0002-9881-4541","observed_orcids":["https://orcid.org/0000-0002-9881-4541"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Cella","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9881-4541","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Michael Wolf","orcid":"https://orcid.org/0000-0003-0259-9945","observed_orcids":["https://orcid.org/0000-0003-0259-9945"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Wolf","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0259-9945","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000660231","display_name":"Steven D. Averbuch","orcid":"https://orcid.org/0000-0002-0210-5901","observed_orcids":["https://orcid.org/0000-0002-0210-5901"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steven D. Averbuch","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Judith Ochs","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Judith Ochs","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5113455755","display_name":"Andrea Kay","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrea Kay","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.9083,"has_fulltext":false,"cited_by_count":97,"citation_normalized_percentile":{"value":0.74966719,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":99},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9580000042915344},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9520000219345093},{"id":"https://openalex.org/keywords/symptom-improvement","display_name":"symptom improvement","score":0.781000018119812},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6909999847412109},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.8799999952316284},{"id":"https://openalex.org/keywords/acne-like-rash","display_name":"acne-like rash","score":0.878000020980835},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.9660000205039978},{"id":"https://openalex.org/keywords/chemotherapy-refractory-disease","display_name":"chemotherapy-refractory disease","score":0.6759999990463257}],"concepts":[{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9701958894729614},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8655135631561279},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7364363074302673},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6966202259063721},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6219480037689209},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5491356253623962},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4758610129356384},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4419293701648712},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.3588448762893677},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3425534963607788}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2336448784","doi":null,"is_oa":false,"landing_page_url":"https://works.bepress.com/joan-schiller/30/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":40,"referenced_works":["https://openalex.org/W1523413020","https://openalex.org/W1653571790","https://openalex.org/W1659692600","https://openalex.org/W1779286308","https://openalex.org/W1803099259","https://openalex.org/W1839238860","https://openalex.org/W1931708823","https://openalex.org/W1985153867","https://openalex.org/W2002602526","https://openalex.org/W2006994284","https://openalex.org/W2007901011","https://openalex.org/W2014725195","https://openalex.org/W2030415021","https://openalex.org/W2038596108","https://openalex.org/W2073464554","https://openalex.org/W2096008575","https://openalex.org/W2104800170","https://openalex.org/W2108523633","https://openalex.org/W2114291028","https://openalex.org/W2126314379","https://openalex.org/W2130652363","https://openalex.org/W2131174104","https://openalex.org/W2135422811","https://openalex.org/W2135911067","https://openalex.org/W2138604360","https://openalex.org/W2139377071","https://openalex.org/W2140626630","https://openalex.org/W2141588257","https://openalex.org/W2142661339","https://openalex.org/W2144932698","https://openalex.org/W2146404049","https://openalex.org/W2150290224","https://openalex.org/W2163402367","https://openalex.org/W2167368130","https://openalex.org/W2171685800","https://openalex.org/W2275508015","https://openalex.org/W2291334052","https://openalex.org/W2528113582","https://openalex.org/W2908778167","https://openalex.org/W3041793038"],"related_works":["https://openalex.org/W2128929678","https://openalex.org/W2034704195","https://openalex.org/W4320890263","https://openalex.org/W2082118762","https://openalex.org/W2380270038","https://openalex.org/W2604612541","https://openalex.org/W2385042273","https://openalex.org/W2369059710","https://openalex.org/W3145798447","https://openalex.org/W2390612351"],"abstract_inverted_index":{"Results":[0],"Of":[1],"221":[2],"patients":[3,22,35,82,153],"enrolled,":[4],"216":[5],"received":[6],"gefitinib":[7,27,65],"as":[8],"randomized.":[9],"Symptoms":[10,77],"of":[11,21,26,34,48,59,64,72,81,108],"NSCLC":[12,155],"improved":[13,78,144],"in":[14,29,46,54,67,79,106,152],"43%":[15],"(95%":[16,31,56,69],"confidence":[17],"interval":[18],"[CI],":[19],"33%-53%)":[20],"receiving":[23,36,61,74],"250":[24,62],"mg":[25,63],"and":[28,66,103,116,133,147],"35%":[30],"CI,":[32,57,70],"26%-45%)":[33],"500":[37,75],"mg.":[38,76],"These":[39],"benefits":[40],"were":[41,96],"observed":[42],"within":[43],"3":[44],"weeks":[45],"75%":[47],"patients.":[49],"Partial":[50],"radiographic":[51,85,112,149],"responses":[52],"occurred":[53],"12%":[55],"6%-20%)":[58],"individuals":[60],"9%":[68],"4%-16%)":[71],"those":[73],"96%":[80],"with":[83,128,154],"partial":[84],"responses.":[86],"The":[87,121],"overall":[88],"survival":[89,119],"at":[90],"1":[91],"year":[92],"was":[93,124],"25%.":[94],"There":[95],"no":[97],"significant":[98],"differences":[99],"between":[100],"the":[101],"250-mg":[102],"500-mg":[104,122],"doses":[105],"rates":[107],"symptom":[109],"improvement":[110],"(P=.26),":[111],"tumor":[113,150],"regression":[114],"(P=.51),":[115],"projected":[117],"1-year":[118],"(P=.54).":[120],"dose":[123],"associated":[125],"more":[126],"frequently":[127],"transient":[129],"acne-like":[130],"rash":[131],"(P=.04)":[132],"diarrhea":[134],"(P=.006).":[135],"Conclusions":[136],"Gefitinib,":[137],"a":[138],"well-tolerated":[139],"oral":[140],"EGFR-tyrosine":[141],"kinase":[142],"inhibitor,":[143],"disease-related":[145],"symptoms":[146],"induced":[148],"regressions":[151],"persisting":[156],"after":[157],"chemotherapy.":[158]},"counts_by_year":[{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":4},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":11},{"year":2012,"cited_by_count":7}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-06-24T00:00:00"}